Cytek Biosciences Inc. (CTKB)
NASDAQ: CTKB
· Real-Time Price · USD
2.42
-0.03 (-1.22%)
At close: May 23, 2025, 3:59 PM
2.42
0.21%
After-hours: May 23, 2025, 05:32 PM EDT
Cytek Biosciences Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Product Revenue | 153.26M | 156.72M | 148.6M | 119.52M |
| Product Revenue Growth | -2.20% | +5.46% | +24.33% | n/a |
| Service Revenue | 47.19M | 36.49M | 15.44M | 8.43M |
| Service Revenue Growth | +29.32% | +136.40% | +83.09% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Asia Pacific Revenue | 35.77M | 31.6M | 22.52M | 16.08M |
| Asia Pacific Revenue Growth | +13.20% | +40.29% | +40.09% | n/a |
| Emea Revenue | 62.34M | 53.18M | 43.96M | 36.97M |
| Emea Revenue Growth | +17.23% | +20.97% | +18.91% | n/a |
| Other Revenue | 9.73M | 6.15M | 2.96M | 2.18M |
| Other Revenue Growth | +58.14% | +107.69% | +35.86% | n/a |
| United States Revenue | 92.61M | 102.08M | 94.59M | 72.72M |
| United States Revenue Growth | -9.28% | +7.92% | +30.07% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 25.41M | 20.94M | 23.37M | 23.96M | 23.95M | 22.32M | 22.43M | 25.15M | 23.23M | 19.54M | 16.85M | 17.02M | 14.51M | 15.23M | 12.24M | 9.74M | 8.26M | 7.19M | 5.53M | 5.57M | 6.07M |
| Selling, General, and Administrative Revenue Growth | +21.31% | -10.39% | -2.47% | +0.05% | +7.33% | -0.49% | -10.84% | +8.30% | +18.85% | +15.97% | -0.96% | +17.28% | -4.75% | +24.49% | +25.63% | +17.92% | +14.91% | +30.01% | -0.77% | -8.19% | n/a |
| Research and Development Revenue | 9.72M | 9.72M | 9.88M | 10M | 9.8M | 10.87M | 11.17M | 12.14M | 9.97M | 9.75M | 8.65M | 8.44M | 8.03M | 7.08M | 6.08M | 6.19M | 5.09M | 4.38M | 3.38M | 2.92M | 3.02M |
| Research and Development Revenue Growth | +0.02% | -1.61% | -1.19% | +2.09% | -9.87% | -2.70% | -7.95% | +21.68% | +2.33% | +12.68% | +2.54% | +5.12% | +13.41% | +16.42% | -1.87% | +21.59% | +16.17% | +29.89% | +15.78% | -3.32% | n/a |
| Sales and Marketing Revenue | 12.51M | 11.87M | 12.43M | 12.27M | 12.54M | 11.56M | 12.08M | 14.37M | 11.14M | 9.03M | 8.81M | 8.43M | 6.96M | 8.3M | 6.33M | 5.58M | 4.28M | 4.56M | 3.84M | 3.06M | 3.53M |
| Sales and Marketing Revenue Growth | +5.35% | -4.47% | +1.31% | -2.19% | +8.49% | -4.26% | -15.95% | +28.91% | +23.44% | +2.49% | +4.50% | +21.14% | -16.18% | +31.16% | +13.54% | +30.37% | -6.21% | +18.81% | +25.47% | -13.37% | n/a |